3-[1-苄基-4-哌啶基]-1H-吲哚 | 179234-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-[1-苄基-4-哌啶基]-1H-吲哚
• 中文别名: 3-(1-苄基哌啶-4-基)-1H-吲哚
• 英文名称: 3-(1-benzylpiperidin-4-yl)-1H-indole
• 英文别名: 3-<1-benzyl-4-piperidinyl>-1H-indole；3-(1-Benzylpiperid-4-yl)-indol
• CAS: 179234-89-0
• 化学式: C₂₀H₂₂N₂
• mdl: MFCD11840337
• 分子量: 290.408
• InChiKey: JXRNDNNHGLPJNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-[1-苄基-4-哌啶基]-1H-吲哚 在 10% Pd on charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 45.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 生成 3-(4’-哌啶基)-1H-吲哚
  参考文献：
  名称：

  Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, Part 1

  摘要：

  A series of new derivatives of 4-aryl-pyrido[1,2-c]pyrimidine containing the 3-(4-piperidyl)-1H-indole residue or its 5-methoxy derivative were synthesized. They were characterized (i) in vitro by binding to 5-HT1A receptors and 5-HT transporter proteins in rat brain cortex membranes and (ii) in vivo in the mouse by induced hypothermia and forced swimming models for antagonist/agonist activity against the 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, respectively. Structure activity relationship evaluation indicated that the presence of the 3-(4-piperidyl)-1H-indole residue and ortho- or para-substituents with -F or -CH3 groups in the aryl ring as well as an unsubstituted aryl in the 4-aryl-pyrido[1,2-c]pyrimidine moiety promoted low K-i values for both receptors. In contrast, the presence of a 5-methoxy-3-(4-piperidyl)-1H-indole methoxy-3-(4-piperidyl)-1H-indole residue as well as -CI or -OCH3 substituents at the para position markedly reduced the receptor affinity. (c) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.09.021
• 作为产物：
  描述：

  3-(1-苄基-1,2,3,6-四氢吡啶-4-基)-1H-吲哚 在 palladium 10% on activated carbon 、 氢气 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 乙酸乙酯 、 1,2-二氯乙烷 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 3-[1-苄基-4-哌啶基]-1H-吲哚
  参考文献：
  名称：

  Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype

  摘要：

  A series of 3-piperidin-4-yl-1H-indoles with building block diversity was synthesized based on a hit derived from an HTS whole-cell screen against Plasmodium falciparum. Thirty-eight compounds were obtained following a three-step synthetic approach and evaluated for anti-parasitic activity. The SAR shows that 3-piperidin-4-yl-1H-indole is intolerant to most N-piperidinyl modifications. Nevertheless, we were able to identify a new compound (10d) with lead-like properties (MW = 305; cLogP = 2.42), showing antimalarial activity against drug-resistant and sensitive strains (EC50 values similar to 3 mu M), selectivity for malaria parasite and no cross-resistance with chloroquine, thus representing a potential new chemotype for further optimization towards novel and affordable antimalarial drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.07.047

文献信息

• 3-&lt;1-alkylenearyl&gt;-4-&lt;1,2,3,6-tetrahydropyridinyl&gt;-and
  申请人：Eli Lilly and Company

  公开号：US05521197A1

  公开（公告）日：1996-05-28

  This invention provides novel 5-HT.sub.1F agonists which are useful for the treatment of migraine and associated disorders having the following formula: ##STR1## wherein A, B, X, Y, Ar and n are defined in the specification.

  这项发明提供了一种新型的5-HT.sub.1F激动剂，可用于治疗偏头痛和相关疾病，其化学结构如下：##STR1##其中A、B、X、Y、Ar和n在说明书中有定义。
• 3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0714894A1

  公开（公告）日：1996-06-05

  This invention provides novel 5-HT1F agonists of formula I which are useful for the treatment of migraine and associated disorders.

  本发明提供了式 I 的新型 5-HT1F 激动剂，可用于治疗偏头痛及相关疾病。
• TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE
  申请人：Iomet Pharma Ltd.

  公开号：EP3082802B1

  公开（公告）日：2020-02-26
• Pharmaceutical Compound
  申请人：IOMET PHARMA LTD

  公开号：US20160367564A1

  公开（公告）日：2016-12-22

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 2 , X 4 , X 10 , and X 11 may be the same or different and each is independently selected from C and N; X 1 , X 3 , X 5 , X 6 , X 7 , X 8 , and X 9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X 4 with the carbon atoms either side of X 2 are single bonds, and are only present when X 2 is absent, X 3 is absent and X 4 is C, and when these bonds are present the ring carbons on each side of X 2 are not directly bonded to each other; each R 1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 1 groups present is such that the valency of X 1 is maintained; each R 12 , R 13 , R 13′ , R 14 , R 15 and R 15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R 16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 16 groups present is such that the valency of X 2 is maintained; each R 17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R 17 groups present is such that the valency of X 3 is maintained; each R 2 , R 3 , R 4 , and R 5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 6 , X 7 , X 8 , and X 9 are maintained; each R 7 , R 8 and R 9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 10 , X 11 , and X 5 are maintained; and R 6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C 1 -C 6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.
• US9931347B2
  申请人：——

  公开号：US9931347B2

  公开（公告）日：2018-04-03